pstowe

HISTORY REPEATS ITSELF: SHORT BMY

Short
NYSE:BMY   Bristol-Myers Squibb Company
BMY is showing erie similarities of its last major cycle, and it appears massive downside is on the horizon. Decreasing RSI, strong support and resistance and the exact same chart pattern are more than enough to show BMY is likely headed down at least 20% over the next few months.

Sizable downside in the overall market over the next few months will likely add to the selling pressure. Price target is $32 by Q4 2019.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.